Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05754528 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance

Study acronym: REaCT-TEMPO
StatusActive, Not Recruiting
PhasePhase 4
Started2023-07-28
View on ClinicalTrials.gov ↗

Amendment history

2026-07-15
Study Status v9
Re-verified, no change to tracked fields
2026-04-01
Study Status v8
Primary completion dateestimated 2025-12→confirmed 2025-11-25
2025-12-12
Study Status v7
Primary completion date2025-11→2025-12
2025-09-29
Study Status, Contacts/Locations, References v6
Primary completion date2025-08→2025-11
Completion date2029-07→2030-02
Study sites1→2
2025-05-14
Study Status, Oversight v5
Primary completion date2025-07→2025-08
Show 4 earlier versions
2024-11-05
Study Status, Oversight v4
Re-verified, no change to tracked fields
2024-08-08
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v3
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2023-08-03
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2025-06→2025-07
Completion date2029-06→2029-07
Start dateestimated 2023-06→confirmed 2023-07-28
Study sites0→1
2023-05-30
Study Status v1
Primary completion date2025-04→2025-06
Completion date2029-04→2029-06
Start date2023-04→2023-06
2023-02-22
Original filing
The goal of this randomized, pragmatic clinical trial is to evaluate an endocrine therapy dose-frequency escalation strategy and its effects on tolerability and compliance. Participants will be randomized to standard daily dosing of endocrine therapy or endocrine therapy dose-frequency escalation defined as, taking endocrine therapy every other day for 1 month and then daily.
Trial Details
NCT Number NCT05754528
Lead Sponsor Ottawa Hospital Research Institute
Conditions Breast Cancer
Enrollment 240 participants
Start Date 2023-07-28
Primary Completion 2025-11-25 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-16